Alport Syndrome
Rare Disease·MeSH: Nephritis, Hereditary
Prevalence
5.0 / 100K
8 drugs in development·6 companies·7 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| bardoxolone | REATA PHARMACEUTICALS INC (RETA) |
Phase 2(6)
Preclinical(1)
| Drug | Company |
|---|---|
| var 200 | ZyVersa Therapeutics, Inc. (ZVSA) |
Compare drugs
Frequently asked questions
How many drugs are in development for Alport Syndrome?
BioSniper tracks 8 drugs in development for Alport Syndrome across 6 companies.
How many clinical trials target Alport Syndrome?
There are 7 clinical trials targeting Alport Syndrome tracked by BioSniper.
What is the prevalence of Alport Syndrome?
The estimated prevalence of Alport Syndrome is approximately 5.0 per 100,000 population.
Deep-dive into Alport Syndrome
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis